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MisoprostolUnsafe abortion causes approximately13% of all maternal deaths worldwide, with higher rates in areas where
abortion access is restricted. Because safe abortion is so low risk, if all women who needed an abortion could
access safe care, this rate would drop dramatically. As women’s health providers and advocates, obstetrician/
gynecologists can support abortion access. By delivering high-quality, evidence-based care ourselves, supporting
other providers who perform abortion, helping women who access abortion in the community, providing
second-trimester care, and improving contraceptive uptake, we can decrease morbidity and mortality from
unsafe abortion.
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Wearemaking progress in the globalﬁght againstmaternal death. Re-
cent estimates from WHO document a 45% decline in maternal deaths
worldwide in the last two decades, from about 523 000 in 1990 to
289000 in 2013 [1]. This trend reﬂects concerted attentionby the interna-
tional health community to achieve the Millennium Development Goals.
Successful efforts have increased skilled birth attendance; improved pre-
natal, delivery, and postpartum care; increased contraceptive prevalence;
and improved sexual and reproductive health services.
Unsafe abortion causes approximately13% of all maternal deaths
worldwide, with higher rates in areas where abortion access is restricted
[2]. Because safe abortion is so low risk, if all womenwho needed an abor-
tion could access safe care, this rate would drop dramatically [2]. In high-
resource regions, the death rate from safe, legal abortion is 0.7 per 100 000
cases. In contrast, the unsafe abortion death rate was estimated to be 520
per 100 000 procedures in Sub-Saharan Africa, 200 per 100 000 in south-
central Asia, and 30 per 100 000 in Latin America as recently as 2008 [2].
In low-resource regions, 41% of unsafe abortions (nearly 9 million
procedures) are among young women aged 15–24 years [3]. Young
women are particularly likely to experience unwanted pregnancy and
to seek abortion from unskilled providers. They are also more likely to
delay seeking both abortion and treatment for resulting complications,
signiﬁcantly increasing their clinical risks [4].
As both healthcare providers and advocates for women, obstetri-
cian/gynecologists have an important role in ensuring that all women
and girls have access to comprehensive reproductive health care,C, 27515, USA. Tel.: +1 919 960
behalf of International Federation ofincluding safe abortion. Effective strategies to increase access to safe
abortion are available, affordable, and well known, but too few stake-
holders prioritize—or even address—this critical issue. By supporting
safe abortion in our clinical practice and beyond, we can signiﬁcantly
reduce a preventable cause of maternal mortality.
2. What can obstetrician/gynecologists do?
Obstetrician/gynecologists care for women throughout their life
cycle, from adolescence through pregnancy and childbirth, to meno-
pause. Unplanned pregnancy is common during the reproductive
years; worldwide, an estimated 40% of all pregnancies are unintended
[5]. Offering a full range of contraceptive options is part of our work
and is as lifesaving a technology for obstetrician/gynecologists as cancer
care or emergency obstetrics. Providing women with a method as soon
as they request it, without unnecessary testing or requirements, can
reduce the risk of unplanned pregnancy.
When awoman ends a pregnancy, obstetrician/gynecologists have a
professional andmoral obligation to assist in her care. FIGO’s Resolution
on Conscientious Objection [6] afﬁrms our obligation to women who
need abortion care. Even doctors who may have a personal objection
to abortion must refer patients for services, provide timely care when
referral is not possible and, in emergency situations, treat women
regardless of their personal beliefs.
Beyond basic care, obstetrician/gynecologists may take a number of
steps to improve abortion access and quality.Most simply,we can incor-
porate evidence-based abortion care into ofﬁce practice and offer
women a full range of contraceptive options as part of the abortion ser-
vice. In addition, we can support nurses, midwives, and other health
professionals to perform abortions, ensure that women who obtain
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Finally, obstetrician/gynecologists can bear witness to the impact of
unsafe abortion and advocate for women’s rights to safe care.
2.1. Offer women evidence-based, quality abortion care
Medical abortion (Box 1) and manual vacuum aspiration can be
done safely, easily, inexpensively, and comfortably in the outpatient
setting. Both WHO and FIGO recommend using medical abortion
and vacuum aspiration rather than sharp curettage, which requires
anesthesia, operating room time and resources, and carries increased
risks to women [7,8].
When incorporating abortion into clinical practice, protocols need to
remain updated. This is especially pertinent with medical abortion.
Resources for updated clinical information includeWHO’s Reproductive
Health Library (http://apps.who.int/rhl/en) and Ipas’s Clinical Updates
in Reproductive Health (www.ipas.org/clinicalupdates).
Staying current with protocols and regimens can be challenging, es-
pecially for practitioners working in low-resource or rural settings with
limited internet access. Reaching remote providers is a priority for orga-
nizations concerned with maternal health outcomes. New avenues for
disseminating evidence, including peer-to-peer support, clinical men-
torship, and mobile networks need to be explored. For example, Ipas
Nigeria piloted a text messaging service for trained uterine evacuation
providers to keep them updated on current evidence and give them re-
mote support. Over the course of a year, Ipas sent 50 to 77 textmessages
with clinical updates, support, and announcements to 163 providers.
The messages were well received, with 90% of providers reporting that
the messages inﬂuenced their patient care and 99% reporting that they
wanted to continue receiving the messages.
Creating a safety culture in health care promotes teamwork, com-
munication, evaluation, and learning from error. When a safety culture
is in place, error reporting improves, adverse events are reduced, burn-
out decreases, and patients have better outcomes [10]. Quality improve-
ment processes promote data tracking and use of quality indicators to
improve patient safety and experience. While much work has occurred
to deﬁne quality in other areas of health care, the deﬁnition of quality in
abortion is still evolving. Abortion quality may include technical skills
(for example, whether vacuum aspiration or medical abortions are
used instead of sharp curettage) along with patient experience (for
example, waiting times at the health center) [11]. Deﬁning quality in
abortion and then putting the processes in place to monitor and
improve it can engage staff, increase safety, and improve women’s
satisfaction with care.Box 1
Medical abortion in the first trimester (up to 12 weeks).
Mifepristone and misoprostol
Up to 9 weeks:
Mifepristone 200 mg orally followed in 24− 48 hours by miso-
prostol 800 μg buccally, vaginally, or sublingually. Buccal miso-
prostol can be used from 9 to 10 weeks.
9 to 12 weeks:
Mifepristone 200mg orally followed 36 to 48 hours later by miso-
prostol 800 μg vaginally then 400 μg vaginally or sublingually up
to four further doses until expulsion of the products of conception.
Misoprostol only (when mifepristone is not available)
Up to 12 weeks:
Misoprostol 800 μg vaginally or sublingually every three but no
more than 12 hours for up to three doses.
Source: WHO [7] and Winikoff et al. [9].2.2. Support other abortion providers
Task-sharing, wheremid-level clinicians deliver reproductive health
interventions, improves women’s access to care. WHO recommends
that nurses, midwives, associate clinicians, and nonspecialist doctors
give all types of reversible contraception, including intrauterine devices
and implants [12]. In addition, ﬁrst-trimester medical abortion and
manual vacuum aspiration are provided as safely and effectively by
nurses, nurse practitioners, midwives, and other health professionals
as by doctors [13]. Expanding the provider pool gives women increased
access and choice about whom they see when they need abortion.
When other health professionals perform abortion, obstetrician/
gynecologists can be a supportive referral partner for complex cases
and women who present at more advanced gestations.
2.3. Support women who access abortion outside the health system
Women have long known about misoprostol’s abortifacient effect
and used it on their own to end unwanted pregnancies, especially in
Latin America, where it has been linked to a decline in abortion-
related morbidity and mortality from more harmful methods [14].
Pharmacists [15], women’s groups, clinicians who deliver informa-
tion in a harm-reduction model [16], and telemedicine or internet pro-
viders [17] assist women in accessing misoprostol outside the health
system. More comprehensive research needs to be done to explore
where women obtain drugs, how they determine eligibility and gesta-
tional age, what regimens and medications they use, and the success
and complication rates of medical abortion outside the health system.
Supporting women who obtain medical abortion outside the health
system is important for clinicians whowork in areaswhere this practice
is prevalent. Partnerships between clinicians and community providers
can ease referrals to the health system for women who are not good
candidates for community-based care or for women who experience
complications.
Women who present to the health system with bleeding or incom-
plete abortion after self-induced or community-based abortion need
safe, respectful, quality services. Treating women for complications of
abortion or incomplete abortion, often known as postabortion care, is
always permissible even if induced abortion is restricted [7].
Finally, understanding why at times women prefer community-
based abortion even when legal services are available can help the
health system improve to meet women’s needs. Women may evaluate
safety differently than obstetrician/gynecologists, preferring services
where they are able to maintain privacy, avoid time off work or away
from family, and prevent legal involvement in their decision to end a
pregnancy even if the clinical risks of community-based treatment are
unknown. Women may not know that they have a legal right to abor-
tion. When clinics and hospitals create barriers for women through
cost, abusive or judgmental handling, unnecessary or expensive testing,
reporting, lack of conﬁdentiality, or inconvenience, women will seek
care elsewhere [18,19].
2.4. Provide second-trimester abortion
Abortions performed at over 12 weeks of gestation make up a rela-
tively small proportion of cases in areaswhere safe abortion is easily ac-
cessible. However, where abortion is restricted, women have a higher
likelihood of presenting in the second trimester, with presentation
rates as high as 17% in Cambodia [20], 35% in Malawi [21], and 41% in
Kenya [22]. Risk factors for second-trimester abortion include young
age, ﬁnancial hardship, domestic violence, and late recognition of
pregnancy. Adolescents in particular are likely to present for care later
in pregnancy [23,24]. Unsafe abortion in the second trimester dispro-
portionately contributes to maternal morbidity and mortality from
abortion, as thesewomen aremore likely to suffer severe complications
and death [25].
Box 2
Medical abortion in the second trimester (12 to 24 weeks).
Mifepristone and misoprostol
Mifepristone 200mg orally followed 36− 48 hours later by miso-
prostol 800 μg vaginally then 400 μg vaginally or sublingually
every three hours for up to four further doses.
Misoprostol only (when mifepristone is not available)
Misoprostol 400 μg vaginally or sublingually every three hours for
up to five doses.
Source: WHO [7].
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methods for second-trimester abortion. Dilation and evacuation re-
quires speciﬁc training, specialized instruments, and an ongoing case
volume to maintain skills. Alternatively, medical abortion using the
WHO-recommended dose of mifepristone and misoprostol in the sec-
ond trimester is highly effective, with complete expulsion rates of
over 98% at 24 hours and 99% at 36 hours, and amedian time to fetal ex-
pulsion of 6.25 hours [26].Misoprostol alone is recommendedwhenmi-
fepristone is not available (Box 2).
Rarely, complications or failure may occur. Because second-
trimester medical abortion complications are similar to obstetric emer-
gencies (for example, hemorrhage or retained placenta), obstetrician/
gynecologists and other obstetric providers already have the skills and
knowledge to treat women. By expanding practice to include second-
trimester medical abortion, obstetrician/gynecologists can provide a
life-saving intervention using familiar skills.2.5. Advocate for women’s access to safe abortion
In addition to making changes to clinical practice, obstetrician/
gynecologists can make invaluable contributions as advocates. Their
ﬁrst-hand experience caring for women makes them powerful wit-
nesses to the harmful impact of restrictive abortion laws and the need
for reform of both policies and practices. Because of their respected po-
sition in society, when doctors speak out, they inﬂuence their peers, the
public, themedia, and policymakers.When Dr Nozer Sheriar speaks to a
global audience aboutwhyheperforms abortion in India (https://www.
youtube.com/watch?v=O6b6huiAOv4), or Dr Willie Parker testiﬁes in
front of the Senate Judiciary Committee to support legislation that pro-
tects abortion access in the USA (http://www.judiciary.senate.gov/imo/
media/doc/07-15-14ParkerTestimony.pdf) their stories put a human
face on the value of safe abortion.
In Ethiopia and Nepal, the support of national obstetrician/
gynecologist associations contributed to successful abortion law reform
and to development of clinical standards and guidelines to help clini-
cians apply the law. Professional associations inmany countries contrib-
ute to FIGO’s Initiative for the Prevention of Unsafe Abortion and its
Consequences and implement the country-based action plans devel-
oped through the initiative. Other advocacy opportunities include serv-
ing on ministry of health advisory boards, mentoring medical students
and trainees, conducting research, writing letters to the editor, visiting
legislative ofﬁces, and serving as expert witnesses.3. Conclusion
Whether telling our patients’ stories, performing abortions our-
selves, or supporting those who do, the obstetrician/gynecologist’s
role as advocates for women can profoundly affect the attitudes and
practices that give women access to safe, respectful, high-quality care.Conﬂict of interest
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